On October 17th, FDA announced that over $23 million in grants will be given to 21 new clinical trial research grants for development work in new therapies/devices for rare diseases over the next four years. The grants were awarded through the Orphan Products Clinical Trials Grants Program.
“We are proud of our 30-year track record of fostering and encouraging the development of safe and effective therapies for rare diseases through our clinical trials grant program,” said Gayatri R. Rao, M.D., J.D., director of FDA’s Office of Orphan Product Development, within the Office of Special Medical Programs. “The grants awarded this year will support much-needed research in 21 different rare diseases, many of which have little, or no, available treatment options.”
Take a look at the press release to see a list of the grant recipients and a description of the study. Need assistance in managing your orphan drug designation or regulatory filing? Contact Pearl Pathways for an experienced team in orphan products.